Innovent’s trial of picankibart for ulcerative colitis meets primary endpoint

Innovent Biologics has reported that its Phase II clinical trial of picankibart (IBI112) in Chinese patients with moderately to severely active ulcerative colitis met the primary endpoint of a 12-week induction period.